MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
Organization & Developments: Theseus Pharmaceuticals
Parents
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
Children
*Biopharmaceutical company focused on treating cancer patients through the discovery, development and commercialization of targeted therapies.
*Theseus product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT
2023: Theseus Pharmaceuticals: Orbimed-Backed Ex-ARIAD Team Developing Next-Gen TKI_seekingalpha.com
Jumps
Finance & Acquisitions: Theseus Pharmaceuticals
Key People: Theseus Pharmaceuticals